18 completed, 8 active not recruiting, 6 recruiting, 6 terminated. 43 Phase 2, 6 Phase 1, 1 Phase 3.
Follow Janssen Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Teclistamab-Daratumumab in AL Amyloidosis Teclistamab, Daratumumab and Hyaluronidase-fihj - Amyloid Light-chain Amyloidosis | Phase 2 | Recruiting | Rajshekhar Chakraborty, MD | 25 | 2025-11-07 | 2026-07-13 |
| Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody Daratumumab, Alemtuzumab, Sirolimus - Sickle Cell Disease | Phase 2 | Recruiting | Children's National Research Institute | 12 | 2024-04-03 | 2025-09-26 |
| Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE) Venetoclax, Dexamethasone, Daratumumab - AL Amyloidosis, Light Chain (AL) Amyloidosis | Phase 1 / Phase 2 | Withdrawn | Alfred Chung, MD | 2024-01-08 | 2025-03-06 | |
| Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma Iberdomide, Daratumumab/rHuPH20 Co-formulation - Multiple Myeloma | Phase 2 | Recruiting | Barbara Ann Karmanos Cancer Institute | 60 | 2023-12-21 | 2026-06-26 |
| A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS) Cyclophosphamide, Bortezomib, Dexamethasone - Multiple Myeloma, Monoclonal Gammopathy of Renal Significance | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2023-10-16 | 2026-07-06 |
| A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy Talquetamab - Multiple Myeloma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 17 | 2023-09-27 | 2026-03-04 |
| Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS), Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS), Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE) - Pulmonary Tuberculosis | Phase 2 | Terminated | Gates Medical Research Institute | 93 | 2023-07-26 | 2026-05-20 |
| Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI Amivantamab, Lazertinib, Zirabev - Non Small Cell Lung Cancer | Phase 2 | Active not recruiting | ETOP IBCSG Partners Foundation | 60 | 2023-03-27 | 2026-01-21 |
| The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults Saline placebo, CD388 - Influenza | Phase 2 | Completed | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 59 | 2022-09-09 | 2024-09-19 |
| Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults Ad26.Mos4.HIV, MVA-BN-HIV, PGT121 - HIV, Acquired Immunodeficiency Syndrome | Phase 1 / Phase 2 | Completed | Boris Juelg, MD PhD | 28 | 2022-04-01 | 2026-05-29 |
| Ad26.COV2.S as a Heterologous Booster in Adults After Single- or Two-Dose of Inactivated COVID-19 Vaccine Full dose of Ad26.COV2. 5x10^10vp, Half dose of Ad26.COV2. 2.5x10^10vp - SARS-CoV-2 Infection | Phase 1 / Phase 2 | Unknown | Mahidol University | 690 | 2021-12-20 | 2022-09-13 |
| A Study of Amivantamab in People With Esophagogastric Cancer Amivantamab - Esophagogastric Cancer | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 25 | 2021-12-02 | 2026-02-17 |
| DARA RVD For High Risk SMM Daratumumab, Bortezomib, Lenalidomide - High-risk Smoldering Multiple Myeloma, Multiple Myeloma | Phase 2 | Active not recruiting | Omar Nadeem, MD | 61 | 2021-03-08 | 2026-07-02 |
| Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab Azacitidine, Daratumumab, Dexamethasone - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Terminated | University of California, San Francisco | 5 | 2020-11-30 | 2024-04-30 |
| A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma Bortezomib, Dexamethasone, Lenalidomide - Multiple Myeloma | Phase 2 | Active not recruiting | University of Miami | 310 | 2020-02-11 | 2026-03-24 |
| Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer Apalutamide, Stereotactic Body Radiation Therapy - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | University of California, San Francisco | 26 | 2019-12-17 | 2026-01-21 |
| Antidepressant Trial With P2X7 Antagonist JNJ-54175446 Active JNJ-54175446, Placebo - Depressive Disorder, Major, Inflammation | Phase 2 | Unknown | CCTU-Core | 142 | 2019-09-12 | 2022-06-22 |
| Pan Tumor Rollover Study Nivolumab, Ipilimumab, Cabozantinib - Cancer | Phase 2 | Recruiting | Bristol-Myers Squibb | 1500 | 2019-08-09 | 2026-10-30 |
| Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery Rivaroxaban 10 MG Oral Tablet [Xarelto] - Bariatric Surgery | Phase 2 | Completed | Insel Gruppe AG, University Hospital Bern | 272 | 2018-07-19 | 2024-11-13 |
| A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation Carfilzomib, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 41 | 2018-07-02 | 2026-06-17 |
Showing 20 of 43. Sign in to see all of them.
Multiple Myeloma (10) · Prostatic Neoplasms (5) · Acquired Immunodeficiency Syndrome (3) · HIV Infections (3) · Immunoglobulin Light-chain Amyloidosis (3) · Infections (2) · Recurrence (2) · AIDS-Related Opportunistic Infections (1) · Alzheimer Disease (1) · Amyloidosis (1) · Anemia, Sickle Cell (1) · Anxiety Disorders (1) · Astrocytoma (1) · COVID-19 (1) · Carcinoma, Non-Small-Cell Lung (1)
daratumumab (15) · Dexamethasone (8) · Lenalidomide (4) · apalutamide (4) · Bortezomib (3) · Calcium Dobesilate (3) · Prednisone (3) · carfilzomib (3) · Bevacizumab (2) · Leuprolide (2) · Temozolomide (2) · abiraterone (2) · amivantamab (2) · ibrutinib (2) · Abiraterone Acetate (1)
United States (32) · United Kingdom (6) · Germany (5) · Spain (4) · Belgium (3) · Canada (3) · France (3) · Greece (3) · Italy (3) · Switzerland (3) · Brazil (2) · Finland (2) · Netherlands (2) · Poland (2) · Puerto Rico (2)
Alfred Chung, MD (2) · Ajay K. Gopal (1) · Arun Anandakumar, MD (1) · Barbara Rothbaum, Ph.D. (1) · Boris D Juelg, MD PHD (1) · Carl Landgren, MD (1) · Daniel George, MD (1) · Darrin Beaupre, MD, PhD (1) · Edward Bullmore (1) · Efstathios Kastritis, Assoc Prof (1) · Evangelos Terpos, Assoc Prof (1) · Fernando Maluf, MD (1)
PMID 23782157, PMID 25381051, PMID 26059948, PMID 26263403, PMID 28750935, PMID 30428049, PMID 31122212, PMID 31533539, PMID 31873746, PMID 31978210, PMID 33259932, PMID 34557563, PMID 34655838, PMID 36413425, PMID 37227726, PMID 37340832, PMID 37344265, PMID 37945755, PMID 38744598, PMID 39804646, PMID 40655875, PMID 41060047, PMID 42833236
2018 (2), 2014 (1), 2017 (1), 2019 (1), P30CA015704 (1), P50CA171963 (1), P50DA033945 (1), U01AI145801 (1)